

Latinx Cancer Care: It's Time for Action!







Cancer in Latinx/Hispanic

- Cancer is the <u>leading cause</u> of death among Latinos, accounting for 22% of deaths
- Utilization of palliative care 2.2% received referral to palliative care services (presented 2018)

Estimated Deaths

Male					Female				
Lung & bronchus 3,400 (17%)					Breast 2,800 (16%)				
Liver & intrahepatic bile duct 2,300 (12%)					Lung & bronchus 2,400 (13%)				
Colon & rectum 2,100 (11%)			1	Colon & rectum 1,700 (9%)					
		Prostate 1,800 (9%)					Pancreas 1,400 (8%)		
		Pancreas 1,400 (7%)					Ovary 1,100 (6%)		
		Stomach 1,000 (5%)		L	iver	&	intrahepatic bil 1,000 (6%)	e duct	t
		Leukemia 1,000 (5%)					Leukemia 800 (4%)		
Non-Hodgkin lymphoma 800 (4%)				Stomach 700 (4%)					
	Ki	dney & renal pe 700 (4%)	lvis			Į	Jterine corpus 700 (4%)		
Brain 8		other nervous system 600 (3%)		n	No	oma			
All sites 19,900 (100%)				All sites 17,900 (100%)					





Figure 2. Leading Sites of New Cancer Cases and Deaths Among Hispanics - 2018 Estimates

Estimated New Cases* Females Males Prostate 13,900 21% Breast 24,000 29% 12% 7,900 Thyroid Colon & rectum 6,800 8% 8% Lung & bronchus 5,600 8% Uterine corpus 6,700 Kidney & renal pelvis Colon & rectum 8% 4,800 7% 6,500 Liver & intrahepatic bile duct Lung & bronchus 4,500 796 5,000 6% Non-Hodgkin lymphoma Non-Hodgkin lymphoma 3,500 4% 3,900 6% Leukemia 3,200 Kidney & renal pelvis 3,200 4% 5% Urinary bladder 2,900 4% Leukemia 2,500 3% 3% Pancreas 2,300 3% Ovary 2,500 Stomach 2,200 3% 2,400 3% Uterine cervix 67,400 All sites 100% All sites 81,700 100%

Estimated Deaths

Males					Females					
Lung & bronchus	3,500	16%			Breast	3,200	16%			
Liver & intrahepatic bile duct	2,700	12%	T		Lung & bronchus	2,600	13%			
Colon & rectum	2,400	11%	A 7		Colon & rectum	1,800	9%			
Prostate	2,000	9%			Pancreas	1,600	8%			
Pancreas	1,700	8%			Liver & intrahepatic bile duct	1,300	6%			
Stomach	1,100	5%			Ovary	1,100	5%			
Leukemia	1,000	5%			Uterine corpus	1,000	5%			
Non-Hodgkin lymphoma	1,000	4%			Leukemia	900	4%			
Kidney & renal pelvis	900	4%	- 1	7	Stomach	800	4%			
Brain & other nervous system	700	3%			Non-Hodgkin lymphoma	700	3%			
All sites	22,300	100%			All sites	20,400	100%			

^{*}Estimates are rounded to the nearest 100 and exclude basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Rankings are based on modeled projections and may differ from the most recent observed data. Estimates exclude Puerto Rico.

©2018, American Cancer Society, Inc. Surveillance Research





Cancer Health Disparities

- Adverse differences between certain population groups in cancer measures:
 - Incidence
 - Stage at diagnosis
 - Mortality
 - Survivorship
 - Screening rates
 - Access to clinical trials



And many more...





Heterogeneous group

- Genetic composition
- Beliefs and perception of health
- "All grouped together"
- Geographic distribution in the U.S.









- New data from ACS: Hispanic/Latinx population in the US has the highest percentage w/o health insurance of any major racial/ethnic group.
- Notably, this group experiences a higher risk of potentially preventable, infection-related cancers.



CA: A Cancer Journal for Clinicians

Article 🗈 Open Access 😊 😧 😑 S

Cancer statistics for the US Hispanic/Latino population, 2021

Kimberly D. Miller MPH , Ana P. Ortiz PhD, MPH, Paulo S. Pinheiro MD, PhD, Priti Bandi PhD, Adair Minihan MPH, Hannah E. Fuchs BS, Dinorah Martinez Tyson PhD, MPH, MA, ... See all authors ~

First published: 21 September 2021 | https://doi.org/10.3322/caac.21695

Disclosures: Kimberly D. Miller, Priti Bandi, Adair Minihan, Hannah E. Fuchs, Stacey A. Fedewa, Ahmedin M. Jemal, and Rebecca L. Siegel are employed by the American Cancer Society, which receives grants from private and corporate foundations, including foundations associated with companies in the health sector for research outside of the submitted work. The authors are not funded by or key personnel for any of these grants and their salaries are solely funded through American Cancer Society funds. Ana Patricia Ortiz reports a University of Puerto Rico/The University of Texas MD Anderson Cancer Center partnership grant (2U54CA096297-16) and consulting fees and speaker fees from Merck. The remaining authors made no disclosures.



Q&A

